{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:21:38Z","timestamp":1792174898270,"version":"4.4.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red","award":["CB21\/13\/00011"],"award-info":[{"award-number":["CB21\/13\/00011"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n and Uni\u00f3n Europea\u2014NextGenerationEU","award":["2171\/2595"],"award-info":[{"award-number":["2171\/2595"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n and Uni\u00f3n Europea\u2014NextGenerationEU","award":["CD23\/00136"],"award-info":[{"award-number":["CD23\/00136"]}]},{"name":"Sara Borrell program"},{"name":"Instituto de Salud Carlos III and MLE"},{"name":"Ministerio de Universidades, Spain"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to investigate factors contributing to non-sustained viral suppression, including intermittent viremia and persistent low-level viremia, during cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) injectable therapy, with a focus on pharmacokinetics (PK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted on people with human immunodeficiency virus (HIV, PWH) transitioning from stable oral antiretroviral therapy (ART) to bimonthly CAB + RPV LA. Standardized follow-up included close monitoring through blood sampling for plasma human immunodeficiency virus type 1 (HIV-1) viral load (VL) and multiple plasma drug concentrations measurements to analyze the connection between PK parameters and virologic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 173 patients with a median (interquartile range [IQR]) follow-up of 11.1(7.1\u201313.2) months and 789 pre-dose measurements, 38.7% experienced VL \u2265 20\u2005copies\/mL, and 16.2% had levels \u226550\u2005copies\/mL. Intermittent viremia occurred in 34.7% of patients, and persistent low-level viremia in 4%. Virological failure developed in 2 cases. Predictors of non-sustained viral suppression included VL at HIV diagnosis (adjusted hazard ratio [AHR]: 1.49 per log10 VL, 95% confidence interval [CI]: 1.04\u20132.12, P = .027), detectable viremia on oral ART (AHR: 2.45, 95% CI: 1.29\u20134.65, P = .006), and the level of viral suppression at transition (AHR: 0.38, 95% CI: .19\u2013.75, P = .004). We found a significant association between low trough concentrations of CAB and RPV and episodes of detectable viremia exceeding 50\u2005copies\/mL. However, none of the assessed PK covariates predicted non-sustained viral suppression in multivariable models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-sustained viral suppression in PWH transitioning from stable oral ART to CAB + RPV LA was linked to preexisting factors before transition. Higher VL pre-ART and incomplete suppression on oral therapy increased the risk, independent of PK parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae475","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:34:56Z","timestamp":1726616096000},"page":"842-853","source":"Crossref","is-referenced-by-count":35,"title":["Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-6867","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez , Alicante ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-8504","authenticated-orcid":false,"given":"Marta","family":"Fern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8022-364X","authenticated-orcid":false,"given":"Christian","family":"Ledesma","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9083-3692","authenticated-orcid":false,"given":"Mar\u00eda","family":"Losada-Echeberr\u00eda","sequence":"additional","affiliation":[{"name":"Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universidad Miguel Hern\u00e1ndez , Elche ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-0795","authenticated-orcid":false,"given":"Enrique","family":"Barraj\u00f3n-Catal\u00e1n","sequence":"additional","affiliation":[{"name":"Institute for Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universidad Miguel Hern\u00e1ndez , Elche ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-3726","authenticated-orcid":false,"given":"Javier","family":"Garc\u00eda-Abell\u00e1n","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez , Alicante ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-1086","authenticated-orcid":false,"given":"Leandro","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-083X","authenticated-orcid":false,"given":"Melissa","family":"Bello-Perez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-7310","authenticated-orcid":false,"given":"Sergio","family":"Padilla","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez , Alicante ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-2458","authenticated-orcid":false,"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital General Universitario de Elche , Elche ,","place":["Spain"]},{"name":"Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez , Alicante ,","place":["Spain"]},{"name":"CIBERINFEC , Instituto de Salud Carlos III, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2025043020405759400_ciae475-B1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2025043020405759400_ciae475-B2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2025043020405759400_ciae475-B3","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48\u2013week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2025043020405759400_ciae475-B4","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025043020405759400_ciae475-B5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"2025043020405759400_ciae475-B6","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96\u2013week results: arandomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"2025043020405759400_ciae475-B7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2025043020405759400_ciae475-B9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025043020405759400_ciae475-B11","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B12","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025043020405759400_ciae475-B13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"},{"key":"2025043020405759400_ciae475-B14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jac\/dkae044","article-title":"Early virological failure with cabotegravir\/rilpivirine","volume":"79","author":"Bail\u00f3n","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025043020405759400_ciae475-B15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis","volume":"79","author":"van Welzen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European Multicenter Cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciad219","article-title":"Plasma human immunodeficiency virus 1 RNA and CD4+ T-cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND Cohort Study","volume":"77","author":"\u00c1lvarez","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B18","doi-asserted-by":"crossref","first-page":"102166","DOI":"10.1016\/j.eclinm.2023.102166","article-title":"Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya","volume":"63","author":"Aoko","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025043020405759400_ciae475-B19","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/cid\/ciz129","article-title":"Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure","volume":"69","author":"Joya","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025043020405759400_ciae475-B20","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","article-title":"Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy","volume":"33","author":"Fleming","year":"2019","journal-title":"AIDS"},{"key":"2025043020405759400_ciae475-B21","doi-asserted-by":"crossref","first-page":"ofae013","DOI":"10.1093\/ofid\/ofae013","article-title":"Clinical relevance of human immunodeficiency virus low-level viremia in the dolutegravir era: data from the Viral Load Cohort North-East Lesotho (VICONEL)","volume":"11","author":"Kohler","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025043020405759400_ciae475-B22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/jac\/dkab025","article-title":"Extensive drug resistance during low- level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre- planned analysis from the SESOTHO trial","volume":"76","author":"Brown","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025043020405759400_ciae475-B23","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1093\/ofid\/ofaa439.1207","article-title":"HIV-1 RNA blips and low-level replication during phase III\/IIIb cabotegravir + rilpivirine long-acting studies are similar to oral 3-drug therapy and not associated with week 48 virologic outcome","volume":"7","author":"Talarico","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025043020405759400_ciae475-B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/QAI.0000000000003320","article-title":"Predictors of post-switch viremia in people with HIV on injectable cabotegravir\/rilpivirine","volume":"95","author":"Hill","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025043020405759400_ciae475-B25","doi-asserted-by":"crossref","first-page":"e4506","DOI":"10.1002\/jms.4506","article-title":"Development and validation of a multiplex UHPLC-MS\/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV","volume":"55","author":"Courlet","year":"2020","journal-title":"J Mass Spectrom"},{"key":"2025043020405759400_ciae475-B26","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","article-title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-na\u00efve adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","volume":"15","author":"Margolis","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2025043020405759400_ciae475-B27","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"2025043020405759400_ciae475-B28","doi-asserted-by":"crossref","first-page":"e00899","DOI":"10.1128\/AAC.00899-16","article-title":"Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals","volume":"61","author":"Aouri","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025043020405759400_ciae475-B29","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the openlabel phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025043020405759400_ciae475-B30","author":"Stanford University"},{"key":"2025043020405759400_ciae475-B31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2025043020405759400_ciae475-B32","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1128\/AAC.01441-15","article-title":"Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation","volume":"59","author":"Dickinson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025043020405759400_ciae475-B33","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/QAI.0000000000003142","article-title":"Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: considerations for dosing schedule and monitoring","volume":"92","author":"Rakhmanina","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025043020405759400_ciae475-B34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","article-title":"Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment","volume":"78","author":"Bernal","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025043020405759400_ciae475-B35","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dkv099","article-title":"Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice","volume":"70","author":"Wirden","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025043020405759400_ciae475-B36","doi-asserted-by":"crossref","first-page":"e0268540","DOI":"10.1371\/journal.pone.0268540","article-title":"Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: a Swedish observational study","volume":"17","author":"Brattg\u00e5rd","year":"2022","journal-title":"PLoS One"},{"key":"2025043020405759400_ciae475-B37","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"key":"2025043020405759400_ciae475-B38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jir208","article-title":"Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy","volume":"204","author":"Chun","year":"2011","journal-title":"J Infect Dis"},{"key":"2025043020405759400_ciae475-B39","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/QAD.0b013e32835a5c2f","article-title":"Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials","volume":"26","author":"Mexas","year":"2012","journal-title":"AIDS"},{"key":"2025043020405759400_ciae475-B40","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2352-3018(24)00063-8","article-title":"Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians","volume":"11","author":"Esteban-Cantos","year":"2024","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae475\/59962259\/ciae475.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/4\/842\/59962259\/ciae475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/4\/842\/59962259\/ciae475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T20:41:11Z","timestamp":1746045671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/4\/842\/7762138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,19]]},"published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae475","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,15]]},"published":{"date-parts":[[2024,9,19]]}}}